Dapagliflozin Confers More Favorable Cardiometabolic Outcomes Vs Vildagliptin | Latest News RSS feed

Dapagliflozin Confers More Favorable Cardiometabolic Outcomes Vs Vildagliptin - Latest News


Dapagliflozin confers more favorable cardiometabolic outcomes vs. vildagliptin

CHICAGO — The SGLT2 inhibitor dapagliflozin was more beneficial than the DPP4 inhibitor vildagliptin in reducing BMI and systolic BP and improving other cardiometabolic outcomes among patients with ... read more

Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes

Although no significant cell death was observed in any treatment group (data not shown), Western blot analysis revealed that high glucose treatment significantly increased caspase 3 protein level (HG ... read more

Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release

[26] Given the high risk of type 2 diabetes, which confers extensive patient suffering and high societal costs, the potential benefit-to-risk ratio of weight-loss treatment could be particularly ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us